Merck Announces Presentation of Interim Data from Study Evaluating Lambrolizumab, an Investigational Anti-PD-1 Antibody, in Patients with Advanced Melanoma at ASCO 2013

Dateline City: 

WHITEHOUSE STATION, N.J.

-Merck Expands Lambrolizumab Clinical Development Program-
-Study Published Online in the New England Journal of Medicine-

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced the presentation of preliminary results from an ongoing
Phase IB expansion study evaluating the safety and efficacy of
lambrolizumab (MK-3475), Merck’s investigational antibody therapy
targeting PD-1, in patients with advanced (inoperable and metastatic)
melanoma.
Language: 

English

Contact HTML: 

MerckMedia Contacts:Ian McConnell, 973-901-5722Cathy Cantone, 908-327-3013orInvestor Contacts:Carol Ferguson, 908-500-1101Justin Holko, 609-915-8293

Ticker Slug: 

Ticker: MRK Exchange: NYSE

read more

Source: Merck.com - Research and Development News - June 2, 2013 Category: Pharmaceuticals Authors: hq_site_admin Tags: Research and Development News Corporate News Latest News Source Type: news